Your browser doesn't support javascript.
Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?
Rangaka, Molebogeng X; Hamada, Yohhei; Abubakar, Ibrahim.
  • Rangaka MX; Institute for Global Health, University College London, London WC1N 1EH, UK; MRC Clinical Trials Unit, University College London, London, UK; Clinical Infectious Diseases Research Initiative (CIDRI)-AFRICA and School of Public Health, University of Cape Town, Cape Town, South Africa. Electronic address: l.rangaka@ucl.ac.uk.
  • Hamada Y; Institute for Global Health, University College London, London WC1N 1EH, UK.
  • Abubakar I; Faculty of Population Health Sciences, University College London, London, UK.
Lancet Respir Med ; 10(6): 529-531, 2022 06.
Article in English | MEDLINE | ID: covidwho-2132824

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis / COVID-19 Type of study: Observational study Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis / COVID-19 Type of study: Observational study Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article